SARS-CoV-2 and Anti-Cardiolipin Antibodies
The current COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to distinct diagnostic and management challenges for front-line healthcare workers. The risk of excessive coagulation activation leading to a cascade of thrombotic events in critically il...
Main Authors: | Mazen Jizzini, Mohsin Shah, Kehua Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-12-01
|
Series: | Clinical Medicine Insights: Case Reports |
Online Access: | https://doi.org/10.1177/1179547620980381 |
Similar Items
-
SARS CoV- 2 vaccination induces antibodies against cardiolipin
by: George Krashias, et al.
Published: (2022-09-01) -
Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies
by: Juan C. Almagro, et al.
Published: (2022-08-01) -
Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies
by: Ruofan Li, et al.
Published: (2022-08-01) -
Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran
by: Ghafari, M, et al.
Published: (2021) -
Anti-SARS-CoV-2 Antibody Testing: Role and Indications
by: Sylvia Mink, et al.
Published: (2023-12-01)